Business Wire

CA-NETAPP

16.3.2022 13:02:09 CET | Business Wire | Press release

Share
NetApp and Cisco Strengthen Partnership Announcing New FlexPod XCS to Extend Converged Infrastructure into the Hybrid Cloud

NetApp (NASDAQ: NTAP), a global, cloud-led, data-centric software company, together with Cisco (NASDAQ: CSCO), today announced the evolution of FlexPod with the introduction of FlexPod® XCS, providing one automated platform for modern applications, data and hybrid cloud services.

FlexPod is composed of pre-validated storage, networking, server technologies from Cisco and NetApp. The new FlexPod XCS platform is designed to accelerate the delivery of modern applications and data in a hybrid cloud environment. FlexPod XCS is the first and only hybrid cloud solution natively integrated across all three major public cloud providers. Additionally, organizations will have the option to use FlexPod-as-a-Service, a pay-as-you-grow pricing model for financial and operational flexibility.

“For years, FlexPod has been helping Presidio customers increase app performance, save software Capex, and decrease unplanned downtime incidents,” said Raphael Meyerowitz, vice president, Engineering at Presidio. “With FlexPod XCS, NetApp and Cisco are providing more flexibility, accessibility and scalability to our customers to deliver a seamless hybrid cloud experience.”

“It is great seeing Cisco and NetApp launching FlexPod XCS together in this hybrid cloud era,” said Jeffrey den Oudsten, Chief Technology Officer at Conscia Netherlands. “Standardization on FlexPod XCS brings rich technologies and huge benefits for us and our customers in various ways, with ability to deliver one point for billing, ordering, support and validated designs. Conscia is determined to facilitate the best hybrid cloud infrastructure for its customers, and together with Cisco and NetApp, we have the best-in-class technology partners helping us to deliver on that promise.”

FlexPod XCS simplifies hybrid cloud operations by increasing accessibility and scalability, extending the infrastructure from an on-premises and edge standard to the hybrid cloud. This new offering lays the groundwork for continued joint innovation that will bring new solutions to market for hybrid cloud, containers, and modern workloads.

FlexPod XCS provides a new set of capabilities to the FlexPod platform:

  • Hybrid Cloud Connectivity: By extending organizations’ data fabric, customers gain the operational certainty of putting the right apps and data in the right place at the right time.
  • Automation: Comprehensive infrastructure automation across all lifecycle phases using Cisco Intersight™ Cloud Orchestrator and NetApp automated scripts and workflows to simplify day-to-day IT operations including configuration, deployment, expansion, and infrastructure consumption and optimization.
  • Visibility: Providing an enhanced and unified view of all FlexPod components through Cisco Intersight, enabling organizations to respond to their business needs more quickly with more intelligent resource decisions
  • FlexPod-as-a-Service: Lowering initial costs for flexibility and tailoring purchasing options based on budgets and usage
  • New Reference Architecture with NetApp Cloud Volumes ONTAP ® (CVO) instances in AWS: FlexPod XCS and ONTAP integration with automation via Cisco Intersight

FlexPod XCS also allows IT departments to gain new insights with full-stack visibility and customized automation capabilities that increase operational productivity. The new FlexPod-as-a-Service consumption model enables customers to have more financial and operational flexibility by aligning costs based on usage.

"Our strategic relationship with NetApp continues to create value for businesses through deep technology integration aimed at solving our customers' biggest challenges,” said Siva Sivakumar, Vice President, Cloud & Compute Product Management, Cisco. “FlexPod XCS powered by Cisco Intersight delivers key new capabilities for our customers such as automation, visibility and hybrid cloud operations into a single unified platform for modern apps, data, and hybrid cloud services.”

“We are proud of our continued innovation with Cisco as we expand FlexPod’s capabilities that solve for organizations’ unique business challenges,” said Mike Arterbury, Vice President, Hybrid Cloud Infrastructure & OEM Solutions at NetApp. “Building on our twelve-year partnership with Cisco, FlexPod XCS combines our best-in-class technologies to simplify the delivery of data and applications, enabling enterprises to run new services more efficiently at the edge, core or in the cloud.”

FlexPod® XCS is in preview for partners and customers and is expected to be generally available globally in mid-2022.

Additional Resources:

About FlexPod

Trusted by thousands of customers across the globe, the enhanced FlexPod XCS platform brings a new level of visibility and automation that can help propel customers’ journey into hybrid cloud operations.​ Composed of prevalidated storage, networking and server technologies, and management software, FlexPod® XCS is designed to increase IT responsiveness to organizational needs providing intelligent insights to optimize costs and performance, support deployment decisions with cloud-like consumption models, and maintain existing configurations across FlexPod infrastructure. By simplifying the delivery of data and applications, enterprises have an advantage of running new services and workloads at the edge, core, or in the cloud.

FlexPod® XCS pricing is mapped to Cisco Intersight Advantage and Premier Tiers and current FlexPod pricing.

About NetApp

NetApp is a global cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

Many of the products and features described herein remain in varying stages of development and will be offered on a when-and-if-available basis. The delivery timeline of these products and features is subject to change at the sole discretion of Cisco or NetApp, and neither Cisco nor NetApp will have liability for delay in the delivery or failure to deliver any of the products or features set forth in this document.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye